Oncology research has been on a 20-year rise and is showing no signs of slowing down anytime in the future. Consider this, between 2000 and 2021, the amount of drugs targeting cancer quadrupled. In 2023, a separate research report found that over 2,000 new oncology clinical trials were launched just that year, and that global spending on cancer medicines “is projected to reach $409 billion by 2028.” Finally, as of May 2025, a search of ClinicalTrials.gov yielded over 39,500 studies indexed under terms including “neoplasm,” “cancer,” and “tumor,” encompassing diverse phases and global locations.

A top global clinical research organization (CRO) partnered with Medable to transform its approach to clinical trial building. Recognizing the inefficiencies in traditional build processes that often “take weeks,” the client leveraged Medable’s Studio platform with its latest AI capabilities to dramatically accelerate timelines, enhance transparency, and improve quality.

‍

‍

Recently, Medable worked with a leading market research consultant to identify the pains and processes that sponsors and CROs encounter when building trials. Of the many that were presented, one issue kept reappearing, the back and forth processes for building COAs. 

This feedback was instrumental in the development of Medable Studio, which was built to simplify the study build process, take eCOA off the critical path, and give sponsors and CROs total control over the trial build process. 

‍